^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

YTS101

i
Other names: YTS101, YT-19/20, CD19/CD20 Dual-CAR-T cells, anti-CD19/CD20 (dual) STAR-T cell therapy, S101, HXYT-001, YTS-001, HXYT001, HXYT 001, YTS001
Associations
Company:
BriSTAR Immunotech
Drug class:
CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy
Related drugs:
Associations
over2years
CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (clinicaltrials.gov)
P1, N=12, Completed, Hebei Yanda Ludaopei Hospital | Suspended --> Completed | Trial completion date: Dec 2022 --> Sep 2021 | Trial primary completion date: Oct 2022 --> May 2021
Trial completion • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 positive • CD19 expression
|
cyclophosphamide • YTS101
over2years
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (clinicaltrials.gov)
P1, N=12, Completed, Hebei Yanda Ludaopei Hospital | Suspended --> Completed | Trial completion date: Dec 2022 --> Feb 2022 | Trial primary completion date: Oct 2022 --> Oct 2021
Trial completion • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 positive • CD19 expression
|
cyclophosphamide • YTS101
over2years
CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (clinicaltrials.gov)
P1, N=12, Suspended, Hebei Yanda Ludaopei Hospital | Trial completion date: Nov 2021 --> Dec 2022 | Recruiting --> Suspended | Trial primary completion date: Aug 2021 --> Oct 2022
Trial completion date • Trial suspension • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 positive • CD19 expression
|
YTS101
over2years
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (clinicaltrials.gov)
P1, N=12, Suspended, Hebei Yanda Ludaopei Hospital | Trial completion date: Nov 2021 --> Dec 2022 | Recruiting --> Suspended | Trial primary completion date: Aug 2021 --> Oct 2022
Trial completion date • Trial suspension • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 positive • CD19 expression
|
YTS101
over2years
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. (clinicaltrials.gov)
P1, N=12, Suspended, Beijing Tsinghua Chang Gung Hospital | Not yet recruiting --> Suspended
Trial suspension • CAR T-Cell Therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 positive • CD19 expression
|
YTS101
almost4years
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Beijing Tsinghua Chang Gung Hospital
Clinical • New P1 trial • CAR T-Cell Therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 positive • CD19 expression
|
YTS101
over4years
Enrollment open • Clinical
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 positive • CD19 expression
|
fludarabine IV • YTS101
over4years
Enrollment open • Clinical
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 positive • CD19 expression
|
YTS101